Press coverage about Sientra (NASDAQ:SIEN) has trended somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sientra earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 45.4712891400395 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Sientra (NASDAQ SIEN) traded down $0.87 on Friday, reaching $11.65. 303,690 shares of the company’s stock were exchanged, compared to its average volume of 127,394. The company has a quick ratio of 1.92, a current ratio of 2.87 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $225.96, a PE ratio of -4.09 and a beta of -1.47. Sientra has a twelve month low of $7.20 and a twelve month high of $16.68.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.06). The firm had revenue of $9.80 million for the quarter, compared to the consensus estimate of $10.54 million. Sientra had a negative net margin of 169.77% and a negative return on equity of 68.82%. The business’s revenue was up 50.8% compared to the same quarter last year. During the same period last year, the company posted ($0.55) EPS. research analysts forecast that Sientra will post -3.23 EPS for the current fiscal year.
A number of brokerages have commented on SIEN. Canaccord Genuity reaffirmed a “buy” rating and set a $14.00 price target on shares of Sientra in a research report on Sunday, October 8th. Zacks Investment Research raised shares of Sientra from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine raised shares of Sientra from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. BidaskClub raised shares of Sientra from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $14.00 price target (up previously from $11.00) on shares of Sientra in a research report on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $15.00.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.